| Abstract: | Datamonitor's Spectrum Pharmaceuticals, Inc. Company Profile is the essential source for top-level company data and information. Spectrum Pharmaceuticals, Inc. Company Profile examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
Spectrum Pharmaceuticals is a biopharmaceutical company that acquires, develops and commercializes a portfolio of oncology and other drug candidates. The company offers Zevalin, a prescribed form of cancer therapy called radio-immunotherapy; and Fusilev for injection, which is indicated after high-dose methotrexate therapy in patients with osteosarcoma. Its preclinical drugs include: SPI-1620, Lucanthone, RenaZorb, Elsamitrucin and Ortataxel. The company primarily operates in US, where it is headquartered in Irvine, California and employs about 84 people. The company recorded revenues of $28.7 million in the fiscal year ended December 2008, compared to the revenues of $7.7 million in the fiscal year 2007. The company's operating loss was $19.2 million in fiscal year 2008, compared to the operating loss of $37.2 million in the fiscal 2007. Its net loss was $15.5 million in fiscal year 2008, compared to the net loss of $34 million in the fiscal 2007.
Scope of the Report
- Provides all the crucial information on Spectrum Pharmaceuticals, Inc. required for business and competitor intelligence needs
-Data is supplemented with details on Spectrum Pharmaceuticals, Inc. history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available statement from Spectrum Pharmaceuticals, Inc.
Reasons to Purchase
- Support sales activities by understanding your customers' businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors' business structure, strategy and prospects
- Obtain the most up to date company information available
|
| Brief Excerpt: | ...Spectrum Phar maceuticals is a biophar maceutical compan y f ocused on cancer and other unmet medical needs .The compan y f ocuses on oncology , urology and other cr itical health challenges .Thecompany pr imarily oper ates in US .The compan y is based in Ir vine, Calif ornia and emplo ys about 50 people .The compan y recorded re venues of $5.7 million dur ing the fiscal y ear ended December 2006, as compared to $0.5 million in the y ear 2005. The oper ating loss of the compan y w as $25.9 million during fiscal y ear 2006, as compared to $19.9 million in fiscal 2005. The net loss w as $23.3 million in fiscal y ear 2006, as compared to $18.6 million in 2005. ...
|
